Goat Anti-Human IgG Fc-PE

Cat. No.
2048-09  
Size
0.25 mg  
Price (USD)
$180.00 
Specificity Reacts with the Fc region of human IgG
Source Pooled antisera from goats hyperimmunized with human IgG
Cross Adsorption Human IgG Fab, IgM, and IgA; may react with IgG from other species
Purification Affinity chromatography on human IgG Fc covalently linked to agarose
Isotype Goat IgG
Isotype Control Goat IgG-PE
Format/Conjugate PE (R-phycoerythrin)
Buffer Formulation Phosphate buffered saline containing 0.1% sodium azide and a stabilizer
Concentration 0.5 mg/mL
Volume 0.5 mL
Storage & Handling 2-8°C; Avoid exposure to light; Do not freeze
Please refer to product specific SDS
Applications
Quality tested applications for relevant formats include -
ELISA 1
FLISA
Other referenced applications for relevant formats include -
Western Blot 2,3
Surface Plasmon Resonance 4
Recommended Dilutions Please refer to product specific Technical Bulletin
RRID AB_2795690
  • FLISA plate was coated with purified human IgG Fc and IgG Fab. Immunoglobulins were detected with serially diluted Goat Anti-Human IgG Fc-PE (SB Cat. No. 2048-09).

FLISA plate was coated with purified human IgG Fc and IgG Fab. Immunoglobulins were detected with serially diluted Goat Anti-Human IgG Fc-PE (SB Cat. No. 2048-09).
 
Related Products (8)
References
1. Wang Q, Chen K, Liu F, Zhao F, Gupta S, Zhang N, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One. 2010;5(9):e12734. (ELISA)
2. Shen X, Hu G, Jiang S, He F, Xing W, Li L, et al. Engineering and characterization of a baculovirus-expressed mouse/human chimeric antibody against transferrin receptor. Protein Eng Des Sel. 2009;22:723-31. (WB)
3. Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J. 2010;277:3039-50. (WB)
4. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-16. (Surface Plasmon Resonance)